1H24 Results Investor Briefing
Released
Released
Announcement PDF
ASX Announcement
22 February 2024
1H24 Results Investor Briefing
Cogstate Ltd (ASX:CGS) has today released an Investor Briefing that provides a summary of the financial results
for the half year ended 31 December 2023 and also provides commentary in respect of the business and financial
outlook.
The presentation material is attached to this announcement.
Additionally, a video recording of Cogstate CEO, Brad O’Connor, CFO, Darren Watson, and Executive Vice
President Clinical Trials, Rachel Colite, presenting these materials, will be available in due course and can be
viewed on the Cogstate Investor Centre homepage:
https://www.cogstate.com/investors/
This announcement was authorised for release by the Board of Directors of Cogstate Ltd.
About Cogstate
Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the
development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable
and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome
assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture. The company’s
clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches,
advanced analytics and scientific consulting. For 20 years, Cogstate has proudly supported the leading-edge research needs of
biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.
In the Healthcare market, in August 2019 Cogstate entered into an exclusive licensing agreement with the pharmaceutical
company Eisai, under which Eisai will market Cogstate technologies as digital cognitive assessment tools in Japanese markets.
In October 2020, Cogstate extended its agreement with Eisai to the Rest of the World. The product, branded as NouKNOW,
launched in Japan on 31 March 2020 (nouknow.jp). For more information, please visit www.cogstate.com.
For further information contact:
Brad O’Connor, Chief Executive Officer, boconnor@cogstate.com
Important Notices
Past performance
Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication of Cogstate's
views on its future financial performance or condition. Past performance of Cogstate cannot be relied upon as an indicator of (and
provides no guidance as to) the future performance of Cogstate. Nothing contained in this announcement nor any information
made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee, whether as to the past,
present or future.
Future performance and forward-looking statements
This announcement contains certain “forward-looking statements”. The words “expect”, “anticipate”, “estimate”, “intend”, “believe”,
“guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are intended to identify forward-looking
statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking
statements. Forward-looking statements, opinions and estimates provided in this announcement are based on assumptions and
contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors
that are beyond the control of Cogstate, its directors and management. Forward-looking statements are provided as a general
guide only and should not be relied upon as an indication or guarantee of future performance.
Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any
projections and assumptions on which these statements are based. These statements may assume the success of Cogstate's
business strategies, including the that the results of any of those strategies will be realised in the period for which the forwardlooking statement may have been prepared or otherwise. For example, Cogstate's performance in any one financial period is
sensitive to whether or not contracts are signed in that period, or a subsequent period, and the rate of enrolment in trials of its
customers which are influenced by factors that are outside of Cogstate's control.
Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation,
none of Cogstate, its representatives or advisers assumes any obligation to update these forward-looking statements. No
representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any
forecasts, prospects, returns or statements in relation to future matters contained in this announcement. The forward-looking
statements are based on information available to Cogstate as at the date of this announcement. Except as required by law or
regulation (including the ASX Listing Rules), none of Cogstate, its representatives or advisers undertakes any obligation to provide
any additional or updated information, whether as a result of a change in expectations or assumptions, new information, future
events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are
also forward-looking statements.
Investor Presentation
February 2024
PRESENTED BY
Brad O’Connor
Darren Watson
Rachel Colite
CEO
CFO
EVP, CLINICAL TRIALS
© 2024 Cogstate Ltd. All rights reserved.
Disclaimer
This presentation has been prepared by Cogstate Limited (‘Cogstate’). The information in this presentation is of a general nature and does not purport to
be complete, nor does it contain all the information which would be required in a prospectus prepared in accordance with the requirements of the
Corporations Act. This presentation may contain statements, opinions, projections, forecasts and other material (forward looking statements), based on
various assumptions. Those assumptions may or may not prove to be correct. None of Cogstate, its respective officers, employees, agents, advisers or
any other person named in this presentation makes any representation as to the accuracy or likelihood of fulfilment of any forward looking statements or
any of the assumptions upon which they are based.
The information contained in this presentation does not take into account the investment objectives, financial situation or particular needs of any recipient
and is not financial product advice. Before making an investment decision, recipients of this presentation should consider their own needs and situation
and, if necessary, seek independent, professional advice.
To the extent permitted by law, Cogstate and its respective officers, employees, agents and advisers give no warranty, representation or guarantee as to
the accuracy, completeness or reliability of the information contained in this presentation. Further, none of Cogstate and its respective officers,
employees, agents and advisers accept, to the extent permitted by law, responsibility for any loss, claim, damages, costs or expenses arising out of, or in
connection with, the information contained in this presentation. Any recipient of this presentation should independently satisfy themselves as to the
accuracy of all information contained herein.
2
Cogstate Well Positioned
1
2
3
Positive Macro Trends
Unique Offering
Financial Strength
CNS / Neuro Growth
Tech & Expertise
Reliable Financial Model
We expect that investment in
central nervous system /
neurological disorders will
provide both near & long term
growth.
Cogstate is a trusted provider of
best-of-breed technology and
services to large pharma
customers.
Profitable, notwithstanding flat
revenues over recent half-year
periods, with demonstrated
leverage to revenue growth.
GROWING MARKET
GROW MARKET SHARE
PROFITABLE GROWTH
3
CNS / Neuro as a Growth
Engine
We expect that Central Nervous System (CNS) /
neurological disorders will be a growth area for
pharma/biotech investment and clinical trials activity
driven by:
1. Increase in positive clinical data.
2. A friendlier regulatory & reimbursement
environment.
3. Big pharma interest in the space.
4
CY2023 Sales Delays
Alzheimer’s disease pause
• Leading companies focused on regulatory submission
• Early stage trials by new names
Rare disease – smaller opportunities
CY2023 Review
• Significant success in CNS indications
• Cogstate strength and area of focus for biotechs
• Nature of trials mean that revenue opportunity is smaller than
other indications
Other factors impacting sales
• Slow down in new study starts across other CNS indications
verified by Cogstate industry partners
• Access to capital has impacted biotechs
5
CY2024 Growth Drivers
Alzheimer’s Disease
Sleep Disorders
Mood Disorders
•
Next generation assets with amyloid focus for early
CY2024
•
Tau mono & combination therapies trials start later in
CY2024
•
Post-marketing trials expected to increase in line with
approvals
•
Pre-screening needs will increase for patient identification
for multiple
careDrivers
pathways (treatment or trial participation)
CY2024 Key
Growth
•
Rare Disease
Increased in-licensing and acquisitions signal late-stage
activity growth (BMS + Karuna; Roche + Ionis and AC
Immune; AbbVie + Cerevel)
Cogstate Advantage
• Unparalleled expertise for pre-symptomatic disease
• Expanding preferred relationships with leaders
Acceleration in new study starts
supported by current sales pipeline
• Unique offering for decentralized / remote approaches
6
CY2024 Growth Drivers
Alzheimer’s Disease
Sleep Disorders
Mood Disorders
Rare Disease
•
Orexin is an exciting area of sleep disorder research
•
Multiple late-stage program initiations planned in multiple
indications
Cogstate Advantage
• Cogstate assessment primary endpoint in phase III
(first in
class)
CY2024narcolepsy
Key Growth
Drivers
• Developed unique solutions to enhance usability,
acceptability and data quality monitoring
Acceleration in new study starts
supported by current sales pipeline
7
CY2024 Growth Drivers
Alzheimer’s Disease
Sleep Disorders
Mood Disorders
•
Trial initiations increasing with new mechanisms (fast
acting, increased durability)
Cogstate Advantage
• Investment in expanded, scalable training and certification
assets
• Remote rating solution; encouraged by regulators
CY2024 Key Growth Drivers
• Strong fit for growing channel partner ecosystem
Rare Disease
Acceleration in new study starts
supported by current sales pipeline
8
CY2024 Growth Drivers
Alzheimer’s Disease
Sleep Disorders
•
Unprecedented phase 2 trial successes leading to phase 3
activity
Cogstate Advantage
• Key Opinion Leader (KOL)
• Longstanding involvement in multiple phase 2 programs
Mood Disorders
CY2024 Key Growth Drivers
Rare Disease
Acceleration in new study starts
supported by current sales pipeline
9
Technology & Expertise
Inch wide, mile deep
•
Specialist provider of best-of-breed solutions
Deep relationships
•
Trusted partner for delivery of global solutions to strategically
important programs
Able to leverage technology
•
License fees only ~18% of revenue, but digital assessments are
key hook to services
Platform agnostic
•
Able to deliver via numerous eCOA (tech) solutions to
accommodate customer requests
Disruptor
•
Rapid adopter of tech or process changes to deliver improved
offering or solve problem (e.g. fully decentralized global phase 3
Alzheimer’s trial)
10
Competition with approved therapies
The launch of new therapies will provide patients with an
option to go onto treatment immediately. That option has
never existed previously.
Alzheimer’s Trial
Challenges
Cogstate is uniquely
positioned to assist with
community-based
assessment
More trials = more patients needed
As new companies begin Alzheimer’s R&D, the demand
for patients will increase.
Regulators demanding greater diversity
The solution to push further into the community, away
from academic research centres, creates new problems.
Alzheimer’s naive sites require more support
More training & better systems that detect (or even
prevent) error.
11
Industry Dynamics – Alzheimer’s Treatment
Individual control
Right patient, right
time
Waiting lists are
the enemy
Biomarkers are
critical
Trial off-ramps
People want agency
over their brain
health
Earlier treatment
provides better
health outcomes
Patients will get
sicker waiting for a
diagnosis
Blood and digital
biomarkers can
speed diagnosis
Out-of-pocket costs
will make treatment
unaffordable for
some
We need to think differently about brain health and
measurement of impairment.
12
Healthcare Offering
Eisai to launch Cognigram to USA physicians
in coming weeks.
Cognigram launch in USA
Prescription of new therapies in USA requires
much more than just cognitive assessment
• Complex differential diagnosis
• Consultation with loved ones/care givers
• Confirmation of amyloid
• Infusion
Cogstate exploring multiple conversations with
pharma and other health care providers
Fundamental belief that technology can
facilitate identification of undiagnosed
cognitive impairment in the community
13
Financial Strength: A focus on profitable growth
•
Proforma financial model provides management with clear guidelines:
–
–
–
–
•
Clinical Trial sales contracts have disappointed against expectations
–
•
See above sales contracts as well as revenue delays on major projects
Cost reduction plans implemented through CY2023
–
•
1H24 $10.9m, 2H23 $6.7m, 1H23 $27.3m
Flat revenue over 4 x half-year periods
–
•
Clinical Trials at 55%-60% margins
Healthcare at higher SaaS margins
Stable cost base
When achieved, EBITDA 25%+, EBIT 20%+ with leverage over stable costs
1H24 Total staff expenses decreased $1.3m (9%) compared to PCP
Profitable half year period
–
$2.1m profit before tax, compared to breakeven PCP
14
1H24 Financial Highlights (All figures in US$)
Clinical sales contracts executed
Contracted future revenue
$10.9m
-60%
Alzheimer’s disease represented 62% of
the value of contracts executed in 1H24
$123.7m
-16%
Profit before Tax
Group Revenue
$20.2m
3%
Clinical Trials up 3% to $17.9m
Healthcare up 1% to $2.2m
Operating net cash flow (excl. passthrough)
17%
Low new contract sales
$2.1m
n/a
Strong improvement from PCP of $0.0m.
Net Cash balance
$0.5m
$24.4m
Increased from PCP due to lower
payments to employees and vendors.
$3.3m lower from PCP of $27.7m due to
share buy-back of $3.1m
-12%
15
Cogstate Group
US$ millions
1H’24
1H’23
YTY %
Revenue
20.2
19.5
3%
Gross Profit
10.8
9.1
19%
GP%
54%
47%
7% Pts
(7.6)
(8.1)
6%
Operating Expense
Depreciation & Amortization
(1.4)
(1.3)
(12%)
EBIT
1.8
(0.2)
n/a
9%
(1%)
10% Pts
Other Income/(Expenses)
0.3
0.2
24%
Net Profit before Tax
2.1
0.0
n/a
EBIT%
Highlights
•
Revenue growth resulting
from Clinical Trials
•
Improving gross profit
margin resulting from May
2023 restructuring actions
•
EBITDA and EBIT margins
improving but not yet at
target model
•
Strong improvement in Net
Profit before Tax
16
Segments
Highlights
Clinical Trials (including Research)
US$ millions
1H’24
1H’23
YTY %
Revenue
17.9
17.3
3%
Direct Costs
(6.8)
(7.5)
9%
SG&A
(2.1)
(2.0)
(1%)
Gross Contribution
9.0
7.8
16%
50%
45%
6% Pts
GP%
Healthcare
•
Growth in revenue, though
impacted by low 2H’23 new
contract sales
•
Improving gross profit margin
with benefit from May 2023
restructuring actions, cost
management, partially offset by
lower than historical average
SW license mix
Healthcare
Revenue
2.2
2.2
1%
Direct Costs
(0.5)
(0.9)
48%
Gross Contribution
1.8
1.3
34%
79%
60%
19% Pts
GP%
Clinical Trials
•
Continuing amortization of
Japan and Global licensing
arrangements, with improving
margins resulting from May 2023
restructuring actions.
17
Cash Flow
US$ millions
1H’24
1H’23
YTY %
Net Profit after Tax
2.0
0.1
n/a
Depreciation & Amortization
1.4
1.3
12%
Disposal of Assets
0.0
0.2
n/a
Non-cash employee benefits
0.7
0.8
(8%)
Grant funding received
(0.1)
(0.2)
(22%)
Exchange Rate differences
(0.3)
(0.2)
60%
Change in working capital
(4.1)
(2.2)
90%
Operating Cash Flow
(0.4)
(0.2)
(67%)
Operating Cash Flow (excl. passthrough)
0.5
0.4
17%
Cash Flow used in investing activities
(0.3)
(1.1)
70%
Cash flow used in Financing activities
(2.6)
(0.3)
(844%)
Total Cash Flow
(3.4)
(1.7)
(103%)
Highlights
•
Decline in receipts from
customers
•
Lower payments to
employees following May
restructure.
•
Lower cash flow used in
Investment activities results
from lower capitalisation of
labour costs
•
Higher cash flow used in
Financing activities due to
share buy-back program
which was $3.1 million
•
US$25.3 million of cash and
cash equivalents on hand.
18
Future Contracted Revenue Run-Off
Highlights
1H24 Act.
Clinical Trials
•
FY24 revenue under
contract of $36.7 million of
which $20.2 is 1H24 actual.
•
FY25 revenue under
contract of $35 million, up
marginally from prior period
compare, largely a result of
movements in existing
projects.
•
FY26, FY27 and FY28+ all
increased from prior
reported periods.
Healthcare
19
Share Buyback
Additional on-market Share Buyback for up to 5 million of Cogstate ordinary shares
•
•
Previous Share Buyback from 28 February 2023 to 4 December 2023
3,753,218 ordinary shares at a total cost of A$5,589,131 acquired on-market
Reflects the belief in the business’ future commercial prospects, the business’ strong capital
position, and supports the Board’s ambition to improve returns for shareholders.
The timing and number of shares to be purchased under the Share Buyback will depend on
the prevailing share price, market conditions and the capital position and requirements over
the next 12 months.
Please refer to the Appendix 3C for further information in respect of the Share Buyback.
20
Recap of Growth Drivers
Short Term
Medium-Long Term
•
•
CNS / Neuro as a growth area in clinical trials
•
Increased R&D activity in Alzheimer’s is the
largest opportunity for Cogstate
•
Alzheimer’s trials will face challenges that
Cogstate is well placed to address
•
Cogstate digital assessments uniquely place
Cogstate in a position to impact:
•
•
•
•
Improvements in Clinical Trials sales contracts
necessary precursor to revenue growth
Previously reported increase in sales activity
and sales pipeline expected to deliver in 2H24
Sales opportunities from growing network of
eCOA and CRO channel partners
Decentralised offering, with increased service
offering providing larger contract value
Financial leverage exists for revenue growth
to translate to profit growth
–
Identification of patients that may benefit
from new treatments; and
–
Pharma push into the community for
patients for trials
21
FY24 Guidance
Customer engagement on new clinical trials
expected to remain strong, particularly in
Alzheimer’s disease.
Expect improved clinical trials sales bookings in
2H24 compared with 1H24, as increased sales
pipeline activity starts to deliver.
The revenue impact of the expected sales
bookings remains sensitive to timing of contract
execution.
22
Share your feedback
Discover